NB-001

DRUG3 trials

Sponsors

NanoBio Corporation, Nobias Therapeutics, Inc.

Conditions

22q11 Deletion SyndromeHerpes LabialisRecurrent Herpes Labialis

Phase 2

Safety, Pharmacokinetics, and Efficacy Study of NB-001 to Treat Recurrent Herpes Labialis

CompletedNCT00453401

NanoBio CorporationHerpes Labialis

Start: 2007-02-28End: 2007-12-31Target: 1000Updated: 2008-05-30

NB-001 in Children and Adolescents With 22q11 Deletion Syndrome

CompletedNCT05290493

Nobias Therapeutics, Inc.22q11 Deletion Syndrome

Start: 2022-02-10End: 2023-06-09Updated: 2025-02-10

Phase 3

A Multicenter Study of NB-001 in the Treatment of Recurrent Herpes Labialis (SHaRCS)

CompletedNCT01324466

NanoBio CorporationRecurrent Herpes Labialis

Start: 2011-04-30End: 2012-01-31Updated: 2013-05-23